- Home
- MRUS vs TFX Comparison
MRUS vs TFX Comparison
Compare MRUS & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRUS
- TFX
- Stock Information
- Founded
- MRUS 2003
- TFX 1943
- Country
- MRUS Netherlands
- TFX United States
- Employees
- MRUS N/A
- TFX N/A
- Industry
- MRUS Biotechnology: Pharmaceutical Preparations
- TFX Medical/Dental Instruments
- Sector
- MRUS Health Care
- TFX Health Care
- Exchange
- MRUS Nasdaq
- TFX Nasdaq
- Market Cap
- MRUS 5.1B
- TFX 5.5B
- IPO Year
- MRUS 2016
- TFX N/A
- Fundamental
- Price
- MRUS $94.81
- TFX $128.12
- Analyst Decision
- MRUS Buy
- TFX Hold
- Analyst Count
- MRUS 18
- TFX 9
- Target Price
- MRUS $93.72
- TFX $141.57
- AVG Volume (30 Days)
- MRUS 2.6M
- TFX 449.0K
- Earning Date
- MRUS 10-31-2025
- TFX 11-06-2025
- Dividend Yield
- MRUS N/A
- TFX 1.06%
- EPS Growth
- MRUS N/A
- TFX N/A
- EPS
- MRUS N/A
- TFX 4.18
- Revenue
- MRUS $56,228,000.00
- TFX $3,041,342,000.00
- Revenue This Year
- MRUS $51.77
- TFX $10.42
- Revenue Next Year
- MRUS N/A
- TFX $10.58
- P/E Ratio
- MRUS N/A
- TFX $30.68
- Revenue Growth
- MRUS 59.77
- TFX 1.11
- 52 Week Low
- MRUS $33.19
- TFX $108.90
- 52 Week High
- MRUS $95.30
- TFX $239.13
- Technical
- Relative Strength Index (RSI)
- MRUS 79.21
- TFX 51.29
- Support Level
- MRUS $94.59
- TFX $130.25
- Resistance Level
- MRUS $95.06
- TFX $134.02
- Average True Range (ATR)
- MRUS 0.36
- TFX 3.54
- MACD
- MRUS -1.00
- TFX 0.35
- Stochastic Oscillator
- MRUS 47.87
- TFX 55.23
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.